<DOC>
	<DOC>NCT01474330</DOC>
	<brief_summary>To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.</brief_summary>
	<brief_title>A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Healthy male subjects of any ethnic origin between ages of 18 and 55 with a body mass index between 19 and 30 1. Any condition, including the presence of laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the Informed Consent Document (ICD), places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study. 2. Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial. 3. Exposure to an investigational drug (new chemical entity) within 30 days prior to the first dose administration or 5 halflives of that investigational drug, if known (whichever is longer).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pomalidomide</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>